Jump Financial LLC Purchases 170,034 Shares of Boston Scientific Corporation $BSX

Key Points

• Jump Financial LLC increased its stake in Boston Scientific by 103.1% during the first quarter, now holding 335,011 shares valued at approximately $33.8 million.
• Insider trading activity shows Boston Scientific's EVP and CEO both sold significant shares of stock recently, with combined sales valued at over $22 million.
• Boston Scientific reported a 22.8% year-over-year revenue growth in its recent earnings, with EPS of $0.75, exceeding analyst expectations of $0.72.

Jump Financial LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 103.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 335,011 shares of the medical equipment provider's stock after buying an additional 170,034 shares during the period. Boston Scientific makes up about 0.5% of Jump Financial LLC's portfolio, making the stock its 18th largest position. Jump Financial LLC's holdings in Boston Scientific were worth $33,796,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Colonial Trust Co SC raised its holdings in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new position in Boston Scientific during the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the first quarter worth about $27,000. Finally, Ameriflex Group Inc. bought a new position in Boston Scientific in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of a number of analyst reports. Morgan Stanley upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. UBS Group upped their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Citigroup reiterated a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Truist Financial lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Trading Up 1.2%

Shares of NYSE BSX traded up $1.31 during mid-day trading on Tuesday, hitting $106.42. The stock had a trading volume of 5,613,286 shares, compared to its average volume of 6,216,135. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1 year low of $79.03 and a 1 year high of $108.94. The business has a 50 day moving average price of $104.18 and a two-hundred day moving average price of $102.12. The firm has a market cap of $157.69 billion, a P/E ratio of 63.35, a price-to-earnings-growth ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $18,347,824.96. This represents a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 345,029 shares of company stock worth $35,976,603. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.